Biomea fusion, inc.BMEA.US Overview
US StockHealthcare
(No presentation for BMEA)
BMEA Overall Performance
BMEA AI Analysis & Strategy
BMEA Recent Performance
2.44%
Biomea fusion, inc.
0.81%
Avg of Sector
-1.14%
S&P500
BMEA PowerScanner
BMEA Key Information
BMEA Valuation Metrics
BMEA Earnings Table
BMEA Profile
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.